WealthAi | $1,000,000 | (Jan 30, 2026)
Checkbox | $23,000,000 | (Jan 30, 2026)
PaleBlueDot AI | $150,000,000 | (Jan 30, 2026)
Certified by Founder
Lodge
Bolden Therapeutics
start up
United States
- Providence, Rhode Island
- 10/01/2024
- Unknown
- Undisclosed Amount
Bolden Therapeutics is a biotechnology company developing first-in-class therapeutics to treat central nervous system diseases such as Alzheimer’s and ischemic stroke. The company’s scientific founders have identified a key molecular pathway to stimulate neural stem cells to promote the birth of new neurons (neurogenesis) in the adult brain. In a proprietary mouse model Bolden has established a proof-of-concept of this approach to increase neurogenesis and enhance hippocampal-dependent memory. The company is actively developing antisense oligonucleotide and monoclonal antibody therapeutics to modulate this pathway.
- Industry Biotechnology Research
- Website https://www.boldentherapeutics.com/
- LinkedIn https://www.linkedin.com/company/bolden-therapeutics/about/
Mesh Security | $12,000,000 | (Jan 30, 2026)
Datalinx AI | $4,200,000 | (Jan 30, 2026)
Ressio Software | Undisclosed Amount | (Jan 30, 2026)
Co-reactive | $7,754,157 | (Jan 30, 2026)
Arkero | $6,000,000 | (Jan 30, 2026)
Redwood Materials | $425,000,000 | (Jan 30, 2026)
Twogee Biotech | $2,575,886 | (Jan 30, 2026)
Levellr | $2,500,000 | (Jan 30, 2026)
Indigo(1) | $50,000,000 | (Jan 30, 2026)
heyData | $16,500,000 | (Jan 30, 2026)